AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update

by Barry101 | May 15, 2023 | Press Release

– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023- Lead clinical program, Phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter...

AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast

by Barry101 | May 9, 2023 | Press Release

OCALA, Fla., May 09, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...

AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)

by Barry101 | Apr 12, 2023 | Press Release

Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”),...

AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions

by Barry101 | Apr 4, 2023 | Press Release

Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditionsOCALA, Fla., April 04, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

by Barry101 | Apr 3, 2023 | Press Release

– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones – Company to host inaugural conference call and webcast...

AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise

by Barry101 | Mar 30, 2023 | Press Release

OCALA, Fla., March 30, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and...